Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651 1658. doi: 10.1056/NEJM200105313442201. 67. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palen- sky J, Wittes J. The effect of spironolactone on morbidity and mor- tality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709 717. doi: 10.1056/NEJM199909023411001. 68. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11 21. doi: 10.1056/ NEJMoa1009492. 69. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator- heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178 187. 70. Taylor AL, Ziesche S, Yancy C, Carson P, D Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African- American Heart Failure Trial Investigators. Combination of isosor- bide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049 2057. doi: 10.1056/NEJMoa042934. 71. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD KH. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547 1552. doi: 10.1056/ NEJM198606123142404. 72. Packer M, O Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 